Existing investors OneVentures and UniQuest led the round. New investors, including members of the company’s board and management team, along with individual investors, participated. The company earmarked proceeds to advance its clinical programs, including its needle-free COVID-19 vaccine candidate.
Other potential uses include the installation of the company’s first manufacturing lines. These would offer the capacity to support Vaxxas’ first products through late-stage clinical studies and early commercial production.